Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 625

1.

Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successes.

Hayes AG, Nutt DJ.

Pharmacol Res Perspect. 2019 Jul 30;7(4):e00510. doi: 10.1002/prp2.510. eCollection 2019 Aug.

2.

Tapering of SSRI treatment to mitigate withdrawal symptoms.

Selvaraj S, Jauhar S, Baldwin DS, Cowen PJ, Goodwin G, Hayes JF, Nutt DJ, Veronese M, Young AH.

Lancet Psychiatry. 2019 Jul;6(7):560-561. doi: 10.1016/S2215-0366(19)30183-X. No abstract available.

PMID:
31230676
3.

Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin.

Lord LD, Expert P, Atasoy S, Roseman L, Rapuano K, Lambiotte R, Nutt DJ, Deco G, Carhart-Harris RL, Kringelbach ML, Cabral J.

Neuroimage. 2019 Oct 1;199:127-142. doi: 10.1016/j.neuroimage.2019.05.060. Epub 2019 May 25.

PMID:
31132450
4.

Antidepressants, withdrawal, and addiction; where are we now?

Jauhar S, Hayes J, Goodwin GM, Baldwin DS, Cowen PJ, Nutt DJ.

J Psychopharmacol. 2019 Jun;33(6):655-659. doi: 10.1177/0269881119845799. Epub 2019 May 21.

PMID:
31111764
5.

Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat.

Jefsen O, Højgaard K, Christiansen SL, Elfving B, Nutt DJ, Wegener G, Müller HK.

Acta Neuropsychiatr. 2019 Aug;31(4):213-219. doi: 10.1017/neu.2019.15. Epub 2019 May 20.

PMID:
31106729
6.

Why Less Is Always More in the Treatment of Alcohol Use Disorders.

Nutt DJ, Gual A, Anderson P, Rehm J.

JAMA Psychiatry. 2019 Apr 1;76(4):359-360. doi: 10.1001/jamapsychiatry.2018.2807. No abstract available.

PMID:
30865234
7.

Using Baclofen to Explore GABA-B Receptor Function in Alcohol Dependence: Insights From Pharmacokinetic and Pharmacodynamic Measures.

Durant CF, Paterson LM, Turton S, Wilson SJ, Myers JFM, Muthukumaraswamy S, Venkataraman A, Mick I, Paterson S, Jones T, Nahar LK, Cordero RE, Nutt DJ, Lingford-Hughes A.

Front Psychiatry. 2018 Dec 14;9:664. doi: 10.3389/fpsyt.2018.00664. eCollection 2018.

8.

Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals.

Nestor LJ, Paterson LM, Murphy A, McGonigle J, Orban C, Reed L, Taylor E, Flechais R, Smith D, Bullmore ET, Ersche KD, Suckling J, Elliott R, Deakin B, Rabiner I, Lingford Hughes A, Sahakian BJ, Robbins TW, Nutt DJ; ICCAM Consortium.

Eur J Neurosci. 2018 Nov 6. doi: 10.1111/ejn.14262. [Epub ahead of print]

PMID:
30402987
9.

GABAA receptor availability is not altered in adults with autism spectrum disorder or in mouse models.

Horder J, Andersson M, Mendez MA, Singh N, Tangen Ä, Lundberg J, Gee A, Halldin C, Veronese M, Bölte S, Farde L, Sementa T, Cash D, Higgins K, Spain D, Turkheimer F, Mick I, Selvaraj S, Nutt DJ, Lingford-Hughes A, Howes OD, Murphy DG, Borg J.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaam8434. doi: 10.1126/scitranslmed.aam8434.

10.

Restrictions on drugs with medical value: Moving beyond stalemate.

Freeman TP, Mehta MA, Neill JC, Nutt DJ, Tunbridge EM, Young AH.

J Psychopharmacol. 2018 Oct;32(10):1053-1055. doi: 10.1177/0269881118798609. Epub 2018 Oct 2. No abstract available.

PMID:
30278146
11.

Psychedelics - Re-opening the doors of perception.

Heal DJ, Henningfield J, Frenguelli BG, Nutt DJ, Smith SL.

Neuropharmacology. 2018 Nov;142:1-6. doi: 10.1016/j.neuropharm.2018.08.024. Epub 2018 Aug 23. No abstract available.

PMID:
30144477
12.

First evaluation of PET-based human biodistribution and radiation dosimetry of 11C-BU99008, a tracer for imaging the imidazoline2 binding site.

Venkataraman AV, Keat N, Myers JF, Turton S, Mick I, Gunn RN, Rabiner EA, Passchier J, Parker CA, Tyacke RJ, Nutt DJ.

EJNMMI Res. 2018 Jul 30;8(1):71. doi: 10.1186/s13550-018-0429-x.

13.

Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals.

Turton S, Myers JF, Mick I, Colasanti A, Venkataraman A, Durant C, Waldman A, Brailsford A, Parkin MC, Dawe G, Rabiner EA, Gunn RN, Lightman SL, Nutt DJ, Lingford-Hughes A.

Mol Psychiatry. 2018 Jun 25. doi: 10.1038/s41380-018-0107-4. [Epub ahead of print]

14.

Effects of psilocybin therapy on personality structure.

Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, Carhart-Harris RL.

Acta Psychiatr Scand. 2018 Nov;138(5):368-378. doi: 10.1111/acps.12904. Epub 2018 Jun 19.

15.

Psilocybin and MDMA reduce costly punishment in the Ultimatum Game.

Gabay AS, Carhart-Harris RL, Mazibuko N, Kempton MJ, Morrison PD, Nutt DJ, Mehta MA.

Sci Rep. 2018 May 29;8(1):8236. doi: 10.1038/s41598-018-26656-2.

16.

Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Site in Human Brain.

Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J, Husbands SM, Rabiner EA, Gunn RN, Murphy PS, Parker CA, Nutt DJ.

J Nucl Med. 2018 Oct;59(10):1597-1602. doi: 10.2967/jnumed.118.208009. Epub 2018 Mar 9.

17.

Cerebral blood flow predicts differential neurotransmitter activity.

Dukart J, Holiga Š, Chatham C, Hawkins P, Forsyth A, McMillan R, Myers J, Lingford-Hughes AR, Nutt DJ, Merlo-Pich E, Risterucci C, Boak L, Umbricht D, Schobel S, Liu T, Mehta MA, Zelaya FO, Williams SC, Brown G, Paulus M, Honey GD, Muthukumaraswamy S, Hipp J, Bertolino A, Sambataro F.

Sci Rep. 2018 Mar 6;8(1):4074. doi: 10.1038/s41598-018-22444-0.

18.

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.

Carrillo F, Sigman M, Fernández Slezak D, Ashton P, Fitzgerald L, Stroud J, Nutt DJ, Carhart-Harris RL.

J Affect Disord. 2018 Apr 1;230:84-86. doi: 10.1016/j.jad.2018.01.006.

PMID:
29407543
19.

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.

Roseman L, Nutt DJ, Carhart-Harris RL.

Front Pharmacol. 2018 Jan 17;8:974. doi: 10.3389/fphar.2017.00974. eCollection 2017.

20.

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.

Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL.

Neuropharmacology. 2018 Nov;142:263-269. doi: 10.1016/j.neuropharm.2017.12.041. Epub 2017 Dec 27.

21.

Psychiatry & the psychedelic drugs. Past, present & future.

Rucker JJH, Iliff J, Nutt DJ.

Neuropharmacology. 2018 Nov;142:200-218. doi: 10.1016/j.neuropharm.2017.12.040. Epub 2017 Dec 25. Review.

22.

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.

Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ.

Psychopharmacology (Berl). 2018 Feb;235(2):399-408. doi: 10.1007/s00213-017-4771-x. Epub 2017 Nov 8.

23.

LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm.

Timmermann C, Spriggs MJ, Kaelen M, Leech R, Nutt DJ, Moran RJ, Carhart-Harris RL, Muthukumaraswamy SD.

Neuropharmacology. 2018 Nov;142:251-262. doi: 10.1016/j.neuropharm.2017.10.039. Epub 2017 Nov 20.

PMID:
29101022
24.

Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.

Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, Curran HV, Carhart-Harris RL.

Psychopharmacology (Berl). 2018 Feb;235(2):459-466. doi: 10.1007/s00213-017-4754-y. Epub 2017 Oct 30.

25.

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.

Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ.

Sci Rep. 2017 Oct 13;7(1):13187. doi: 10.1038/s41598-017-13282-7.

26.

Cannabis Dampens the Effects of Music in Brain Regions Sensitive to Reward and Emotion.

Freeman TP, Pope RA, Wall MB, Bisby JA, Luijten M, Hindocha C, Mokrysz C, Lawn W, Moss A, Bloomfield MAP, Morgan CJA, Nutt DJ, Curran HV.

Int J Neuropsychopharmacol. 2018 Jan 1;21(1):21-32. doi: 10.1093/ijnp/pyx082.

27.

Serotonin and brain function: a tale of two receptors.

Carhart-Harris RL, Nutt DJ.

J Psychopharmacol. 2017 Sep;31(9):1091-1120. doi: 10.1177/0269881117725915. Epub 2017 Aug 31. Review.

28.

Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.

Murphy A, Nestor LJ, McGonigle J, Paterson L, Boyapati V, Ersche KD, Flechais R, Kuchibatla S, Metastasio A, Orban C, Passetti F, Reed L, Smith D, Suckling J, Taylor E, Robbins TW, Lingford-Hughes A, Nutt DJ, Deakin JFW, Elliott R; ICCAM Platform.

Neuropsychopharmacology. 2017 Aug;42(9):1925-1926. doi: 10.1038/npp.2017.99.

29.

Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.

Law FD, Diaper AM, Melichar JK, Coulton S, Nutt DJ, Myles JS.

J Psychopharmacol. 2017 Aug;31(8):1046-1055. doi: 10.1177/0269881117711710. Epub 2017 Jun 20.

30.

The Standard Joint Unit.

Casajuana Kögel C, Balcells-Olivero MM, López-Pelayo H, Miquel L, Teixidó L, Colom J, Nutt DJ, Rehm J, Gual A.

Drug Alcohol Depend. 2017 Jul 1;176:109-116. doi: 10.1016/j.drugalcdep.2017.03.010. Epub 2017 May 16.

PMID:
28531767
31.

Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.

Murphy A, Nestor LJ, McGonigle J, Paterson L, Boyapati V, Ersche KD, Flechais R, Kuchibatla S, Metastasio A, Orban C, Passetti F, Reed L, Smith D, Suckling J, Taylor E, Robbins TW, Lingford-Hughes A, Nutt DJ, Deakin JF, Elliott R; ICCAM Platform.

Neuropsychopharmacology. 2017 Jun;42(7):1559. doi: 10.1038/npp.2017.47. No abstract available.

32.

Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery.

Savulich G, Riccelli R, Passamonti L, Correia M, Deakin JF, Elliott R, Flechais RS, Lingford-Hughes AR, McGonigle J, Murphy A, Nutt DJ, Orban C, Paterson LM, Reed LJ, Smith DG, Suckling J, Tait R, Taylor EM, Sahakian BJ, Robbins TW, Ersche KD.

Transl Psychiatry. 2017 Mar 7;7(3):e1054. doi: 10.1038/tp.2017.34.

33.

Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals.

Morris LS, Baek K, Tait R, Elliott R, Ersche KD, Flechais R, McGonigle J, Murphy A, Nestor LJ, Orban C, Passetti F, Paterson LM, Rabiner I, Reed L, Smith D, Suckling J, Taylor EM, Bullmore ET, Lingford-Hughes AR, Deakin B, Nutt DJ, Sahakian BJ, Robbins TW, Voon V; ICCAM Consortium.

Addict Biol. 2018 Jan;23(1):425-436. doi: 10.1111/adb.12503. Epub 2017 Feb 28.

34.

Addiction research and theory: a commentary on the Surgeon General's Report on alcohol, drugs, and health.

Badiani A, Berridge KC, Heilig M, Nutt DJ, Robinson TE.

Addict Biol. 2018 Jan;23(1):3-5. doi: 10.1111/adb.12497. Epub 2017 Feb 21.

35.

Concerns regarding conclusions made about LSD-treatments (received 25 October 2016).

Erritzoe D, Nutt DJ, Carhart-Harris R.

Hist Psychiatry. 2017 Jun;28(2):257-260. doi: 10.1177/0957154X17692197. Epub 2017 Feb 15. No abstract available.

PMID:
28198192
36.

Altered Insula Connectivity under MDMA.

Walpola IC, Nest T, Roseman L, Erritzoe D, Feilding A, Nutt DJ, Carhart-Harris RL.

Neuropsychopharmacology. 2017 Oct;42(11):2152-2162. doi: 10.1038/npp.2017.35. Epub 2017 Feb 14.

37.

Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.

Murphy A, Nestor LJ, McGonigle J, Paterson L, Boyapati V, Ersche KD, Flechais R, Kuchibatla S, Metastasio A, Orban C, Passetti F, Reed L, Smith D, Suckling J, Taylor E, Robbins TW, Lingford-Hughes A, Nutt DJ, Deakin JF, Elliott R.

Neuropsychopharmacology. 2017 Apr;42(5):1049-1057. doi: 10.1038/npp.2016.289. Epub 2017 Jan 2. Erratum in: Neuropsychopharmacology. 2017 Jun;42(7):1559. Neuropsychopharmacology. 2017 Aug;42(9):1925-1926.

38.

Thirty years of Journal of Psychopharmacology.

Nutt DJ.

J Psychopharmacol. 2016 Nov;30(11):1071. No abstract available.

PMID:
27834755
39.

Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity.

Mick I, Ramos AC, Myers J, Stokes PR, Chandrasekera S, Erritzoe D, Mendez MA, Gunn RN, Rabiner EA, Searle GE, Galduróz JCF, Waldman AD, Bowden-Jones H, Clark L, Nutt DJ, Lingford-Hughes AR.

Addict Biol. 2017 Nov;22(6):1601-1609. doi: 10.1111/adb.12457. Epub 2016 Oct 13.

40.

The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description.

McGonigle J, Murphy A, Paterson LM, Reed LJ, Nestor L, Nash J, Elliott R, Ersche KD, Flechais RS, Newbould R, Orban C, Smith DG, Taylor EM, Waldman AD, Robbins TW, Deakin JW, Nutt DJ, Lingford-Hughes AR, Suckling J; ICCAM Platform.

J Psychopharmacol. 2017 Jan;31(1):3-16. doi: 10.1177/0269881116668592. Epub 2016 Oct 4.

41.

Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task.

Nestor LJ, Murphy A, McGonigle J, Orban C, Reed L, Taylor E, Flechais R, Paterson LM, Smith D, Bullmore ET, Ersche KD, Suckling J, Tait R, Elliott R, Deakin B, Rabiner I, Lingford-Hughes A, Nutt DJ, Sahakian B, Robbins TW; ICCAM Consortium.

Addict Biol. 2017 Nov;22(6):1576-1589. doi: 10.1111/adb.12444. Epub 2016 Sep 6.

42.

Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses.

Lawn W, Freeman TP, Pope RA, Joye A, Harvey L, Hindocha C, Mokrysz C, Moss A, Wall MB, Bloomfield MA, Das RK, Morgan CJ, Nutt DJ, Curran HV.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3537-52. doi: 10.1007/s00213-016-4383-x. Epub 2016 Sep 2.

43.

Question-based Drug Development for psilocybin - Authors' reply.

Carhart-Harris RL, Nutt DJ.

Lancet Psychiatry. 2016 Sep;3(9):807. doi: 10.1016/S2215-0366(16)30217-6. No abstract available.

PMID:
27568266
44.

Behavioural tasks sensitive to acute abstinence and predictive of smoking cessation success: a systematic review and meta-analysis.

Grabski M, Curran HV, Nutt DJ, Husbands SM, Freeman TP, Fluharty M, Munafò MR.

Addiction. 2016 Dec;111(12):2134-2144. doi: 10.1111/add.13507. Epub 2016 Aug 8. Review.

45.

Don't panic. A guide to tryptophan depletion with disorder-specific anxiety provocation.

Hood SD, Bell CJ, Argyropoulos SV, Nutt DJ.

J Psychopharmacol. 2016 Nov;30(11):1137-1140. Epub 2016 Jun 20. Review.

PMID:
27329165
46.

Significant reductions in human visual gamma frequency by the gaba reuptake inhibitor tiagabine revealed by robust peak frequency estimation.

Magazzini L, Muthukumaraswamy SD, Campbell AE, Hamandi K, Lingford-Hughes A, Myers JF, Nutt DJ, Sumner P, Wilson SJ, Singh KD.

Hum Brain Mapp. 2016 Nov;37(11):3882-3896. doi: 10.1002/hbm.23283.

47.

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ.

Lancet Psychiatry. 2016 Jul;3(7):619-27. doi: 10.1016/S2215-0366(16)30065-7. Epub 2016 May 17.

48.

A pilot study of the effect of short-term escitalopram treatment on brain metabolites and gamma-oscillations in healthy subjects.

Maron E, Near J, Wallis G, Stokes M, Matthews PM, Nutt DJ.

J Psychopharmacol. 2016 Jun;30(6):579-80. doi: 10.1177/0269881116636108. No abstract available.

49.

LSD-induced entropic brain activity predicts subsequent personality change.

Lebedev AV, Kaelen M, Lövdén M, Nilsson J, Feilding A, Nutt DJ, Carhart-Harris RL.

Hum Brain Mapp. 2016 Sep;37(9):3203-13. doi: 10.1002/hbm.23234. Epub 2016 May 6.

50.

LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion.

Roseman L, Sereno MI, Leech R, Kaelen M, Orban C, McGonigle J, Feilding A, Nutt DJ, Carhart-Harris RL.

Hum Brain Mapp. 2016 Aug;37(8):3031-40. doi: 10.1002/hbm.23224. Epub 2016 Apr 29.

Supplemental Content

Support Center